# IMNM — Immunome Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** IMNM  
**Sources:** 20  
**Published:** 2026-10-27  
**Canonical:** https://app.k3vl4r.com/research/deep-research-imnm-immunome-inc-catalysts-narrative-risks-9639

---

## Overview

Immunome, Inc. (Nasdaq: IMNM) is a clinical-stage targeted oncology company developing antibody-drug conjugates (ADCs), radioligand therapies, and the small-molecule gamma secretase inhibitor varegacestat (formerly AL102) for desmoid tumors [[3]](https://www.metatrader.com/en/symbols/nasdaq/imnm/documents/3077376-current-report-02-oct-2026), [[13]](https://investors.immunome.com/news-releases/), [[16]](https://www.rttnews.com/companies/44281/immunome-inc-imnm). The stock closed around $17.40–$17.58 in mid-October 2026, with a market cap of ~$2.12B as of 2026-10-25 [background], [[8]](https://www.msn.com/en-us/money/other/william-blair-initiates-coverage-of-immunome-at-outperform/ar-AA2epIfT?ocid=BingNewsVerp), [[9]](https://www.msn.com/en-us/money/other/william-blair-initiates-coverage-of-immunome-at-outperform/ar-AA2epIfT). Below are the recent catalysts, bull/bear narratives, risks, and scheduled events, drawn from primary and secondary sources.

## Recent Catalysts (July–October 2026)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-imnm-immunome-inc-catalysts-narrative-risks-9639 (free to sign up)._